{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,26]],"date-time":"2026-07-26T02:55:44Z","timestamp":1785034544937,"version":"3.55.0"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2013,10,23]],"date-time":"2013-10-23T00:00:00Z","timestamp":1382486400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2013,10,23]],"date-time":"2013-10-23T00:00:00Z","timestamp":1382486400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2014,4]]},"DOI":"10.1038\/leu.2013.309","type":"journal-article","created":{"date-parts":[[2013,10,23]],"date-time":"2013-10-23T12:39:59Z","timestamp":1382531999000},"page":"941-944","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Inhibition of JAK3 with a novel, selective and orally active small molecule induces therapeutic response in T-cell malignancies"],"prefix":"10.1038","volume":"28","author":[{"given":"J A","family":"Ross","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Spadaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D C","family":"Rosado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F","family":"Cavallo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R A","family":"Kirken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F","family":"Pericle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,10,23]]},"reference":[{"key":"BFleu2013309_CR1","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1038\/nri2304","volume":"8","author":"I Aifantis","year":"2008","unstructured":"Aifantis I, Raetz E, Buonamici S . Molecular pathogenesis of T-cell leukaemia and lymphoma. Nat Rev Immunol 2008; 8: 380\u2013390.","journal-title":"Nat Rev Immunol"},{"key":"BFleu2013309_CR2","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1056\/NEJMoa1110169","volume":"366","author":"M Schrappe","year":"2012","unstructured":"Schrappe M, Hunger SP, Pui CH, Saha V, Gaynon PS, Baruchel A et al. Outcomes after induction failure in childhood acute lymphoblastic leukemia. N Engl J Med 2012; 366: 1371\u20131381.","journal-title":"N Engl J Med"},{"key":"BFleu2013309_CR3","doi-asserted-by":"publisher","first-page":"2144","DOI":"10.1038\/leu.2012.74","volume":"26","author":"T Bains","year":"2012","unstructured":"Bains T, Heinrich MC, Loriaux MM, Beadling C, Nelson D, Warrick A et al. Newly described activating JAK3 mutations in T-cell acute lymphoblastic leukemia. Leukemia 2012; 26: 2144\u20132146.","journal-title":"Leukemia"},{"key":"BFleu2013309_CR4","doi-asserted-by":"publisher","first-page":"2746","DOI":"10.1182\/blood-2008-06-164368","volume":"113","author":"MG Cornejo","year":"2009","unstructured":"Cornejo MG, Kharas MG, Werneck MB, Le Bras S, Moore SA, Ball B et al. Constitutive JAK3 activation induces lymphoproliferative syndromes in murine bone marrow transplantation models. Blood 2009; 113: 2746\u20132754.","journal-title":"Blood"},{"key":"BFleu2013309_CR5","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/j.humpath.2005.07.011","volume":"36","author":"R Lai","year":"2005","unstructured":"Lai R, Rassidakis GZ, Lin Q, Atwell C, Medeiros LJ, Amin HM . Jak3 activation is significantly associated with ALK expression in anaplastic large cell lymphoma. Hum Pathol 2005; 36: 939\u2013944.","journal-title":"Hum Pathol"},{"key":"BFleu2013309_CR6","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1111\/j.1600-065X.2008.00754.x","volume":"228","author":"K Ghoreschi","year":"2009","unstructured":"Ghoreschi K, Laurence A, O\u2019Shea JJ . Janus kinases in immune cell signaling. Immunol Rev 2009; 228: 273\u2013287.","journal-title":"Immunol Rev"},{"key":"BFleu2013309_CR7","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1126\/science.270.5237.794","volume":"270","author":"DC Thomis","year":"1995","unstructured":"Thomis DC, Gurniak CB, Tivol E, Sharpe AH, Berg LJ . Defects in B lymphocyte maturation and T lymphocyte activation in mice lacking Jak3. Science 1995; 270: 794\u2013797.","journal-title":"Science"},{"key":"BFleu2013309_CR8","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1111\/j.1600-065X.2008.00644.x","volume":"223","author":"M Pesu","year":"2008","unstructured":"Pesu M, Laurence A, Kishore N, Zwillich SH, Chan G, O'Shea JJ . Therapeutic targeting of Janus kinases. Immunol Rev 2008; 223: 132\u2013142.","journal-title":"Immunol Rev"},{"key":"BFleu2013309_CR9","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1038\/nbt1358","volume":"26","author":"MW Karaman","year":"2008","unstructured":"Karaman MW, Herrgard S, Treiber DK, Gallant P, Atteridge CE, Campbell BT et al. A quantitative analysis of kinase inhibitor selectivity. Nat Biotechnol 2008; 26: 127\u2013132.","journal-title":"Nat Biotechnol"},{"key":"BFleu2013309_CR10","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1002\/art.33419","volume":"64","author":"JM Kremer","year":"2012","unstructured":"Kremer JM, Cohen S, Wilkinson BE, Connell CA, French JL, Gomez-Reino J et al. A phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and an inadequate response to methotrexate alone. Arthritis Rheum 2012; 64: 970\u2013981.","journal-title":"Arthritis Rheum"},{"key":"BFleu2013309_CR11","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1097\/01.TP.0000157117.30290.6F","volume":"79","author":"DC Borie","year":"2005","unstructured":"Borie DC, Changelian PS, Larson MJ, Si MS, Paniagua R, Higgins JP et al. Immunosuppression by the JAK3 inhibitor CP-690\u2009550 delays rejection and significantly prolongs kidney allograft survival in nonhuman primates. Transplantation 2005; 79: 791\u2013801.","journal-title":"Transplantation"},{"key":"BFleu2013309_CR12","doi-asserted-by":"publisher","first-page":"4236","DOI":"10.4049\/jimmunol.175.7.4236","volume":"175","author":"SM Stepkowski","year":"2005","unstructured":"Stepkowski SM, Kao J, Wang ME, Tejpal N, Podder H, Furian L et al. The Mannich base NC1153 promotes long-term allograft survival and spares the recipient from multiple toxicities. J Immunol 2005; 175: 4236\u20134246.","journal-title":"J Immunol"},{"key":"BFleu2013309_CR13","doi-asserted-by":"publisher","first-page":"5399","DOI":"10.1038\/sj.onc.1206849","volume":"22","author":"HM Amin","year":"2003","unstructured":"Amin HM, Medeiros LJ, Ma Y, Feretzaki M, Das P, Leventaki V et al. Inhibition of JAK3 induces apoptosis and decreases anaplastic lymphoma kinase activity in anaplastic large cell lymphoma. Oncogene 2003; 22: 5399\u20135407.","journal-title":"Oncogene"},{"key":"BFleu2013309_CR14","doi-asserted-by":"publisher","first-page":"2407","DOI":"10.1182\/blood-2006-04-020305","volume":"108","author":"L Qiu","year":"2006","unstructured":"Qiu L, Lai R, Lin Q, Lau E, Thomazy DM, Calame D et al. Autocrine release of interleukin-9 promotes Jak3-dependent survival of ALK+ anaplastic large-cell lymphoma cells. Blood 2006; 108: 2407\u20132415.","journal-title":"Blood"},{"key":"BFleu2013309_CR15","doi-asserted-by":"publisher","first-page":"825","DOI":"10.2353\/ajpath.2009.080982","volume":"175","author":"J Dien Bard","year":"2009","unstructured":"Dien Bard J, Gelebart P, Anand M, Zak Z, Hegazy SA, Amin HM et al. IL-21 contributes to JAK3\/STAT3 activation and promotes cell growth in ALK-positive anaplastic large cell lymphoma. Am J Pathol 2009; 175: 825\u2013834.","journal-title":"Am J Pathol"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/leu2013309.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/leu2013309","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/leu2013309.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T15:23:58Z","timestamp":1648740238000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/leu2013309"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,10,23]]},"references-count":15,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2014,4]]}},"alternative-id":["BFleu2013309"],"URL":"https:\/\/doi.org\/10.1038\/leu.2013.309","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,10,23]]},"assertion":[{"value":"23 October 2013","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}